As of 2025-09-17, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -47.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 4,180.35 mil USD. ARWR's TTM EBITDA according to its financial statements is -87.91 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 15.7x | 14.5x |
| Forward P/E multiples | 15.8x - 18.6x | 17.1x |
| Fair Price | (10.86) - (10.81) | (10.86) |
| Upside | -136.9% - -136.7% | -136.9% |
| Date | EV/EBITDA |
| 2025-09-16 | -47.55 |
| 2025-09-15 | -46.37 |
| 2025-09-12 | -48.02 |
| 2025-09-11 | -48.02 |
| 2025-09-10 | -46.72 |
| 2025-09-09 | -44.89 |
| 2025-09-08 | -44.01 |
| 2025-09-05 | -47.01 |
| 2025-09-04 | -45.32 |
| 2025-09-03 | -45.00 |
| 2025-09-02 | -41.67 |
| 2025-08-29 | -35.93 |
| 2025-08-28 | -36.42 |
| 2025-08-27 | -35.55 |
| 2025-08-26 | -34.59 |
| 2025-08-25 | -33.85 |
| 2025-08-22 | -34.83 |
| 2025-08-21 | -33.92 |
| 2025-08-20 | -33.05 |
| 2025-08-19 | -32.52 |
| 2025-08-18 | -32.60 |
| 2025-08-15 | -33.54 |
| 2025-08-14 | -30.82 |
| 2025-08-13 | -32.72 |
| 2025-08-12 | -29.28 |
| 2025-08-11 | -28.35 |
| 2025-08-08 | -27.11 |
| 2025-08-07 | -26.54 |
| 2025-08-06 | -26.93 |
| 2025-08-05 | -27.19 |
| 2025-08-04 | -27.18 |
| 2025-08-01 | -26.34 |
| 2025-07-31 | -26.13 |
| 2025-07-30 | -25.98 |
| 2025-07-29 | -26.32 |
| 2025-07-28 | -26.76 |
| 2025-07-25 | -26.04 |
| 2025-07-24 | -26.85 |
| 2025-07-23 | -26.32 |
| 2025-07-22 | -24.81 |
| 2025-07-21 | -24.42 |
| 2025-07-18 | -27.64 |
| 2025-07-17 | -30.93 |
| 2025-07-16 | -30.06 |
| 2025-07-15 | -29.01 |
| 2025-07-14 | -30.55 |
| 2025-07-11 | -30.08 |
| 2025-07-10 | -30.94 |
| 2025-07-09 | -30.98 |
| 2025-07-08 | -28.87 |